# EDGAR Filing Document

**Accession Number:** 0001503802
**File Stem:** 0000000000-23-001718
**Filing Date:** 2023-2
**Character Count:** 3350
**Document Hash:** a789f40cd2a8c9cc75f380735a2a90dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001718.hdr.sgml**: 20230605

**ACCESSION NUMBER**: 0000000000-23-001718

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230221

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Karyopharm Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001503802
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 263931704
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 85 WELLS AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02459
- **BUSINESS PHONE:** 617-658-0600

**MAIL ADDRESS:**
- **STREET 1:** 85 WELLS AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02459
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-23-041600

## Text-Extract

```

United States securities and exchange commission logo

                          February 21, 2023

       Michael Mano
       Senior Vice President and General Counsel
       Karyopharm Therapeutics Inc.
       85 Wells Avenue, 2nd Floor
       Newton, MA 02459

                                                        Re: Karyopharm
Therapeutics Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed February 17,
2023
                                                            File No. 333-269846

       Dear Michael Mano:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Arzhang
Navai at 202-551-4676 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Craig Hilts

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 21, 2023

Michael Mano
Senior Vice President and General Counsel
Karyopharm Therapeutics Inc.
85 Wells Avenue, 2nd Floor
Newton, MA 02459

**Re: Karyopharm Therapeutics Inc.**
**Registration Statement on Form S-3**
**Filed February 17, 2023**
**File No. 333-269846**

Dear Michael Mano:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Arzhang Navai at 202-551-4676 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Craig Hilts